No serious adverse events or deaths were reported in this study, indicating that the FKN-CX3CR1 blockade intervention is safe and well-tolerated, and may have a positive clinical effect in patients with highly active rheumatoid arthritis (52, 53). The gene discussed is CX3CR1; the disease is rheumatoid arthritis.